Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study
Authors:
- 6 February 2020
- journal article
- research article
- Published by Springer Nature in Acta Diabetologica
- Vol. 57 (7) , 809-818
Abstract
Lowering postprandial lipemia may mitigate cardiovascular risk in patients with diabetic dyslipidemia. This study was aimed to investigate whether saroglitazar suppresses postprandial lipemia in patients with diabetes and dyslipidemia.Keywords
Funding Information
- Cadila Healthcare Limited
This publication has 35 references indexed in Scilit:
- Standards of Medical Care in Diabetes—2013Diabetes Care, 2012
- Insulin Resistance, Hyperglycemia, and AtherosclerosisCell Metabolism, 2011
- Fasting Compared With Nonfasting Triglycerides and Risk of Cardiovascular Events in WomenJAMA, 2007
- Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover studyDiabetes/Metabolism Research and Reviews, 2007
- Demystifying triglycerides: a practical approach for the clinician.Cleveland Clinic Journal of Medicine, 2005
- Emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndromeThe American Journal of Cardiology, 2004
- Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetesDiabetes/Metabolism Research and Reviews, 2002
- Insulin resistance and cardiovascular diseaseJournal of Clinical Investigation, 2000
- Dietary treatment of the metabolic syndrome — the optimal dietBritish Journal of Nutrition, 2000
- Postprandial lipoproteins and progression of coronary atherosclerosisAtherosclerosis, 1994